Cognition Therapeutics Advances DLB Treatment, Eyes FDA Meeting
Event summary
- Cognition Therapeutics is advancing zervimesine (CT1812) for the treatment of dementia with Lewy bodies (DLB) psychosis, following positive Phase 2 SHIMMER trial results.
- The company expects to meet with the FDA's Division of Psychiatry in Q2 2026 to discuss a registrational plan for DLB psychosis.
- A Phase 2 START study in 545 patients with MCI and early Alzheimer's disease is fully enrolled and data readout is expected in 2H 2027, funded by an NIH grant.
- Zervimesine demonstrated a 95% reduction in cognitive decline in patients with low p-tau217 levels in a Phase 2 Alzheimer's study.
The big picture
Cognition's focus on DLB psychosis represents a strategic shift towards a smaller, underserved market with potentially less competition than the broader Alzheimer's space. The reliance on NIH grants underscores the company's funding challenges and dependence on external sources. The observed efficacy in patients with lower p-tau217 levels suggests a biomarker-driven approach to Alzheimer's treatment, a growing trend in the field.
What we're watching
- Regulatory Risk
- The upcoming FDA meeting will be critical; a less-than-positive outcome could significantly impact the DLB psychosis development timeline and valuation.
- Clinical Efficacy
- The success of the START trial, particularly in patients with low p-tau217 levels, will determine the viability of zervimesine as an Alzheimer's treatment.
- Concomitant Use
- Data on the use of zervimesine alongside existing therapies like Kisunla and Leqembi will be informative regarding market adoption and potential combination strategies.
Related topics